De Antonio I, Torres-Jiménez R, Verdú-Pérez A, Prior de Castro C, García-Puig J
Servicio de Bioquímica Clínica. Servicio de Medicina Interna. Hospital La Paz. Facultad de Medicina. Universidad Autónoma. Madrid, España.
Rev Neurol. 2002;35(9):877-83.
We have reviewed the treatments employed to alleviate the different manifestations of the Lesch Nyhan syndrome, the adverse reactions related to these treatments, and the prospectives of future therapeutic approaches now under active research.
Lesch Nyhan syndrome is an X linked inherited disorder of purine metabolism caused by the deficiency of the enzyme hypoxanthine guanine phosphoribosyltransferase (HPRT). Clinical features include overproduction of uric acid and a neurologic syndrome related to the severity of the enzyme defect.
Treatment with xanthine oxidase inhibitors is effective for the control of the elevated renal excretion of uric acid, but there is no specific treatment for the neurologic symptoms. Due to the low frequency of the syndrome and to the incomplete understanding of the pathophysiologic mechanisms underlying the neurologic manifestations, the treatments employed are merely symptomatic.
我们回顾了用于缓解莱施-奈恩综合征不同表现的治疗方法、与这些治疗相关的不良反应以及目前正在积极研究的未来治疗方法的前景。
莱施-奈恩综合征是一种X连锁遗传性嘌呤代谢紊乱疾病,由次黄嘌呤鸟嘌呤磷酸核糖转移酶(HPRT)缺乏引起。临床特征包括尿酸过度产生以及与酶缺陷严重程度相关的神经综合征。
黄嘌呤氧化酶抑制剂治疗对控制尿酸肾排泄升高有效,但对神经症状没有特异性治疗方法。由于该综合征发病率低且对神经表现背后的病理生理机制了解不全面,所采用的治疗仅为对症治疗。